NANTES, France--(BUSINESS WIRE)--Regulatory News: OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced that the United States Patent and Trademark Office has granted a new patent ...
OSE Immunotherapeutics Selects Chronic Pouchitis and Hidradenitis Suppurativa as New Key Indications for Lusvertikimab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results